Literature DB >> 9252153

Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat.

T Daemen1, M Velinova, J Regts, M de Jager, R Kalicharan, J Donga, J J van der Want, G L Scherphof.   

Abstract

Liposomes with diameters of 200 to 400 nm containing phosphatidylserine (PS) or phosphatidylglycerol (PG) were injected intravenously into rats. Two hours after injection, 75% of the injected dose of PS liposomes was found in the liver and only 10% found in the spleen, while 35% of the PG liposomes was found in the liver and as much as 40% was found in the spleen. Cell-isolation experiments revealed the following remarkable difference in the intrahepatic distribution between the two liposome formulations: the PS liposomes distributed in about equal amounts to Kupffer cells and hepatocytes, despite their size (200-400 nm) exceeding that of the endothelial fenestrae (average 150 nm), whereas the PG liposomes were only taken up by the Kupffer cells and not at all by the hepatocytes. Double-label studies, using liposomes in which the lipid-moiety was radio labeled with [3H]cholesteryloleylether ([3H]CE) and the water phase with [14C]sucrose, showed that the liposomes were taken up as intact particles. These observations were confirmed through electron microscopy by determining the in situ localization of liposome-encapsulated colloidal gold particles in thin sections of liver and spleen. The differences in organ distribution are ascribed to differences in opsonization patterns of the two liposomal surfaces. For the difference in intrahepatic distribution, we offer the following two explanations: the exploitation of the blood cell-mediated forced sieving concept and the indication of a PS-specific pharmacological effect on the dimensions of the fenestrations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252153     DOI: 10.1002/hep.510260223

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.

Authors:  Elisabeth J Ruijgrok; Marcel H A M Fens; Irma A J M Bakker-Woudenberg; Els W M van Etten; Arnold G Vulto
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue.

Authors:  R M Schiffelers; G Storm; I A Bakker-Woudenberg
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

3.  Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate.

Authors:  Kenneth J Longmuir; Sherry M Haynes; Janie L Baratta; Natasha Kasabwalla; Richard T Robertson
Journal:  Int J Pharm       Date:  2009-08-05       Impact factor: 5.875

4.  Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection.

Authors:  M M Gaspar; S Neves; F Portaels; J Pedrosa; M T Silva; M E Cruz
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 5.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

6.  Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence.

Authors:  Kenneth J Longmuir; Richard T Robertson; Sherry M Haynes; Janie L Baratta; Alan J Waring
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

7.  Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells.

Authors:  Martin Bartsch; Alida H Weeke-Klimp; Dirk K F Meijer; Gerrit L Scherphof; Jan A A M Kamps
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

8.  Nanoparticle transport pathways into tumors.

Authors:  S M Moghimi; D Simberg
Journal:  J Nanopart Res       Date:  2018-06-21       Impact factor: 2.253

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.